

Select 2025 Pipeline Catalysts

Anticipated Regulatory Decisions

Compound	Indication	
ABRYSVO (EU)	RSV Infection (18-59 Years)	✓
ADCETRIS	DLBCL	✓
BRAFTOVI	1L BRAFm mCRC (PFS)	
TALZENNA + XTANDI	mCRPC all-comers	✓

Anticipated Phase 3 Readouts

Compound	Indication	
BRAFTOVI (BREAKWATER PFS)	1L BRAFm mCRC	✓
ELREXFIO	DCE Multiple Myeloma	
HYMPAVZI	Hemophilia A or B with Inhibitors	✓
Inclacumab	Sickle Cell Disease	
PADCEV*	MIBC	
Sasanlimab (subq PD-1)	NMIBC	✓
TALZENNA + XTANDI	1L CSPC	
TUKYSA	HER2+ BC	
Vepdegestrant	2L ER+ mBC	✓

Potential Pivotal Program Starts

Compound	Indication	
1H 2025		
Atirmociclib (CDK4i)	1L mBC	✓
Mevrometostat + XTANDI (MEVPRO-3)	1L mCSPC	
Sigvotatug vedotin (SV)**	1L PD-L1-High NSCLC	
2H 2025		
<i>C. difficile</i> Vaccine - Updated Formulation	<i>C. difficile</i> Infection	
Danuglipron	Chronic Weight Management	✓
KAT6i	2L mBC	
NURTEC	Menstrual Migraine	✓
PCV 25-valent	Pneumococcal Infection (Adult)	
PDL1V ADC	1L mHNSCC	
PDL1V ADC	2L+ NSCLC	
Ponsegromab	Cancer Cachexia	
Vepdegestrant + Atirmociclib	1L mBC	✓
Vepdegestrant + CDK4/6i	2L+ mBC	✓

* Study sponsored by Merck; potential based on interim analysis | ** Emerging data from ongoing studies will inform additional Phase 3 starts in 1L NSCLC

Note: Some pivotal program starts may be subject to generation of positive data in earlier-stage studies and/or alignment with regulatory agencies

Note: Many Phase 3 studies are event-driven and readouts are therefore subject to change

Co-development partners: Adcetris (Takeda), Padcev (Astellas), vepdegestrant (Arvinas), Xtandi (Astellas)

ADC=Antibody-drug conjugate; BC=breast cancer; BRAFm=BRAF-mutant; *C. difficile*=*Clostridioides difficile*; CSPC=castration-sensitive prostate cancer; DCE=double-class exposed; DLBCL=Diffuse large B-cell lymphoma; ER+=estrogen-receptor positive; HER2+=human epidermal growth factor receptor 2 positive; mBC=metastatic breast cancer; mCRC=metastatic colorectal cancer; mCRPC=metastatic castration-resistant prostate cancer; mCSPC=metastatic castration-sensitive prostate cancer; mHNSCC=metastatic head and neck squamous cell carcinoma; MIBC=muscle-invasive bladder cancer; NMIBC=non-muscle invasive bladder cancer; NSCLC=non-small-cell lung cancer; PCV=pneumococcal conjugate vaccine; PD-1=programmed cell death protein-1; PD-L1=programmed death ligand-1; PD-L1-high= $\geq 50\%$ of tumor cells expressing PD-L1; RSV=respiratory syncytial virus; subq=subcutaneous



[✓] completed

[✓] completed; did not achieve OR didn't meet primary endpoint OR development discontinued/no longer planned